Human autologous adipose-derived mesenchymal progenitor cell therapy (Cellular Biomedicine Group)

N/A

Report date: 2026/02/06 20:01:23

Base Information

Drug NameHuman autologous adipose-derived mesenchymal progenitor cell therapy (Cellular Biomedicine Group)
Drug Alias NamehaMPC - Cellular Biomedicine GroupReJoin
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapyCell and gene therapy > Cell therapy > Source of cells > Adipose-derived
Mechanisms of ActionCell replacements
TargetsNot applicable
Therapy Area/IndicationsOsteoarthritis, Knee
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaPending
Originator CompaniesShanghai Jiaotong UniversityCellular Biomedicine (Shanghai) Co LtdBiolife Solutions
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCellular Biomedicine Group LtdShanghai Ninth People'S Hospital Affiliated To Shanghai Jiao Tong University
Active IndicationsN/A
Inactive IndicationsOsteoarthritis, Knee

Other Information

ATC CodeN/A
Related LinksN/A